Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study

Abstract Introduction The dynamic range of cerebrospinal fluid (CSF) amyloid β (Aβ1–42) measurement does not parallel to cognitive changes in Alzheimer's disease (AD) and cognitively normal (CN) subjects across different studies. Therefore, identifying novel proteins to characterize symptomatic AD s...

Description complète

Détails bibliographiques

Auteurs principaux:	Yuk Yee Leung, Jon B. Toledo, Alexey Nefedov, Robi Polikar, Nandini Raghavan, Sharon X. Xie, Michael Farnum, Tim Schultz, Young Baek, Vivianna M. Van Deerlin, William T. Hu, David M. Holtzman, Anne M. Fagan, Richard J. Perrin, Murray Grossman, Holly D. Soares, Mitchel A. Kling, Matthew Mailman, Steven E. Arnold, Vaibhav A. Narayan, Virginia M‐Y. Lee, Leslie M. Shaw, David Baker, Gayle M. Wittenberg, John Q. Trojanowski, Li‐San Wang, Alzheimer's Disease Neuroimaging Initiative
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2015-09-01
Collection:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Sujets:	Cerebrospinal fluid Biomarkers Alzheimer's disease Cognitive impairment Amyloid beta Dementia
Accès en ligne:	https://doi.org/10.1016/j.dadm.2015.06.008
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!